Hypothesis

Neuronal activity patterns bias the conformational selection of tau oligomers toward a specific, export‑competent strain that preferentially uses tunneling nanotubes (TNTs) for intercellular transfer, thereby linking connectome dynamics to the spatial spread of pathology.

Mechanistic Basis

Recent work shows that tau aggregation follows a nucleation‑dependent polymerization model where slow oligomer formation precedes rapid fibril elongation 1. Structural analyses of 27 tau amyloid fibrils have identified distinct conformers that correlate with Alzheimer’s disease and CTE 2. Treatments that alter the energy landscape of monomer‑oligomer equilibria can shift the population toward off‑pathway or on‑pathway species 3. Meanwhile, tau spreads prion‑like through neural networks, yet the exact intercellular route—exocytosis, axonal flow, or TNTs—remains unresolved 4.

We propose that active synapses generate local calcium fluxes and kinase activity (e.g., GSK‑3β, MARK) that transiently phosphorylate tau at specific sites, stabilizing a compact oligomeric conformation with exposed hydrophobic patches. This strain exhibits a higher affinity for TNT formation because its surface promotes membrane curvature and actin‑based protrusion. Inactive or low‑firing neurons favor alternative oligomers that are retained intracellularly or cleared by proteasomes. Thus, the connectome’s functional architecture—not just its static topology—determines which tau strains are released and where they travel.

Testable Predictions

1. Pharmacological shift: Stabilizing tau monomers with a small‑molecule binder (e.g., a phenothiazine derivative) will reduce the proportion of the export‑competent oligomer strain in vitro, measured by conformation‑specific antibodies or seeded‑fibril assays, without altering total tau levels.
2. Activity correlation: In vivo chemogenetic excitation of a defined cortical column will increase TNT‑mediated tau transfer to synaptically connected targets, detectable by retrograde labeling of tau‑TNT complexes; silencing the same column will decrease transfer.
3. Strain specificity: Antibodies that recognize the export‑competent tau conformation will block TNT‑mediated spread in microfluidic neuronal cultures, whereas antibodies against generic tau oligomers will not.
4. Connectome mapping: Longitudinal PET using a tracer that preferentially binds the export‑competent strain will show spread patterns that correlate better with functional connectivity (fMRI) than with anatomical distance alone.

Experimental Design

• In vitro: Differentiate human iPSC‑derived neurons, treat with activity modulators (TTX, bicuculline, optogenetic stimulation), and quantify oligomeric strains via dot blot with conformation‑specific antibodies and ELISA for TNT‑associated tau (co‑staining for actin and tau).
• In vivo: Use Cre‑dependent DREADDs in mice expressing human tau P301S. Stimulate or inhibit specific cortical layers while performing longitudinal tau‑PET with a strain‑sensitive tracer (to be developed). Post‑mortem, assess TNT formation via electron microscopy and tau distribution.
• Validation: Knock‑out of M-sec (a TNT‑essential gene) should abolish activity‑dependent spread without affecting oligomer formation, confirming the mechanistic link.

If these experiments confirm that neuronal activity gates a particular tau strain’s use of TNTs, the hypothesis will redefine therapeutic strategies: targeting activity‑dependent conformational selection or TNT formation may halt spread more effectively than global aggregation inhibitors.